Continuous Expression of Interferon Regulatory Factor 4 Sustains CD8

Journal

Research (Washington, D.C.)
ISSN: 2639-5274
Titre abrégé: Research (Wash D C)
Pays: United States
ID NLM: 101747148

Informations de publication

Date de publication:
2023
Historique:
received: 08 08 2023
accepted: 01 11 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 5 1 2024
Statut: epublish

Résumé

T-cell-based immunotherapy is gaining momentum in cancer treatment; however, our comprehension of the transcriptional regulation governing T cell antitumor activity remains constrained. The objective of this study was to explore the function of interferon regulatory factor 4 (IRF4) in antitumor CD8

Identifiants

DOI: 10.34133/research.0271 PMID: 38178902 PMC: PMC10765897
pubmed: 38178902
doi: 10.34133/research.0271
pii: 0271
pmc: PMC10765897
doi:

Types de publication

Journal Article

Langues

eng

Pagination

0271

Informations de copyright

Copyright © 2023 Anze Yu et al.

Déclaration de conflit d'intérêts

Competing interests: The authors declare that they have no competing interests.

Auteurs

Anze Yu (A)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
ORCID: 0000-0002-3998-1198

Jinfei Fu (J)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.

Zheng Yin (Z)

Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, TX, USA.
Department of Radiology, Houston Methodist Hospital, Weill Cornell Medicine, Houston, TX, USA.

Hui Yan (H)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.

Xiang Xiao (X)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.

Dawei Zou (D)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.

Xiaolong Zhang (X)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.

Xiongbing Zu (X)

Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Xian C Li (XC)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Department of Surgery, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Wenhao Chen (W)

Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute and Institute for Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Department of Surgery, Weill Cornell Medicine, Cornell University, New York, NY, USA.
ORCID: 0000-0002-0626-3739

Classifications MeSH